Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1425 of 1475 entries
View as:

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Phase: N/A Priority: Normal
NCT ID: NCT03634969 Org: User:
Start: 08/14/18 End: 04/30/19 Due: 04/30/20

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00605618 Org: User:
Start: 03/31/08 End: 03/31/09 Due: 03/31/10

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01658878 Org: User:
Start: 10/30/12 End: 11/12/24 Due: 11/12/25

Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients

Phase: N/A Priority: Normal
NCT ID: NCT02456844 Org: User:
Start: 05/31/15 End: 07/31/15 Due: 07/31/16

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02905266 Org: User:
Start: 10/27/16 End: 10/25/19 Due: 10/25/20

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT00754325 Org: User:
Start: 09/30/08 End: 01/31/14 Due: 01/31/15

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06211179 Org: User:
Start: 01/10/24 End: 06/13/24 Due: 06/13/25

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT05556265 Org: User:
Start: 11/08/22 End: 05/16/24 Due: 05/16/25

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03662659 Org: User:
Start: 10/16/18 End: 01/18/24 Due: 01/18/25

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06544655 Org: User:
Start: 10/10/24 End: 10/14/27 Due: 10/14/28

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02872116 Org: User:
Start: 10/12/16 End: 06/06/24 Due: 06/06/25

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Phase: N/A Priority: Normal
NCT ID: NCT00550017 Org: User:
Start: 12/31/07 End: 03/31/10 Due: 03/31/11

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00116415 Org: User:
Start: 03/31/02 End: 11/30/04 Due: 11/30/05

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT02754141 Org: User:
Start: 06/21/16 End: 10/12/21 Due: 10/12/22

Safety Study of BMS-816336 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00979368 Org: User:
Start: 11/30/09 End: 02/28/10 Due: 02/28/11

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06086886 Org: User:
Start: 11/16/23 End: 12/20/24 Due: 12/20/25

Safety Profile of Nulojix in Home Infusion Settings

Phase: N/A Priority: Normal
NCT ID: NCT02500498 Org: User:
Start: 10/31/14 End: 06/30/15 Due: 06/30/16

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00324155 Org: User:
Start: 08/31/06 End: 10/31/13 Due: 10/31/14

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04730349 Org: User:
Start: 06/03/21 End: 06/22/22 Due: 06/22/23

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Phase: N/A Priority: Normal
NCT ID: NCT01837719 Org: User:
Start: 04/30/13 End: 06/30/13 Due: 06/30/14

Expanded Access for Repotrectinib

Phase: N/A Priority: Normal
NCT ID: NCT05926232 Org: User:
Start: - End: - Due: -

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

Phase: N/A Priority: Normal
NCT ID: NCT04141228 Org: User:
Start: 11/29/16 End: 05/31/18 Due: 05/31/19

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00569036 Org: User:
Start: 04/30/08 End: 04/30/13 Due: 04/30/14

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Phase: N/A Priority: Normal
NCT ID: NCT01472081 Org: User:
Start: 02/09/12 End: 06/03/21 Due: 06/03/22

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

Phase: N/A Priority: Normal
NCT ID: NCT01439204 Org: User:
Start: 10/31/11 End: 02/29/12 Due: 02/28/13